Gilead Sciences begins phase III trial of leukaemia drugZenopaThe first patient has been dosed as part of Study 116, a trial that will assess the safety and efficacy of the drug in combination with rituximab among 160 subjects across Europe and the US….

Lupus Nephritis: First ACR Guidelines PublishedMedscapeRituximab or calcineurin inhibitors should be considered if standard treatments fail." Dr. Hahn also noted that an algorithm for management of pregnant woman with active [LN] is included in th…

New biologics and biosimilars approval guidelines in MexicoThe Pharma LetterFor example, Probiomed already sells six non-originator biologics, including Kikuzubam (rituximab), which is Probiomed's version of Roche's Rituxan/MabThera (rituximab)…

In Mexico, New Guidelines Are Now in Effect for the Market Authorization of …EON: Enhanced Online News (press release)For example, Probiomed already sells six non-originator biologics, including Kikuzubam (rituximab), which is Probiomed's version…

Gilead Pushes Cancer Pipeline; Enters Phase III with PI3K DrugBioWorld OnlineIn the trial, called Study 116, 160 patients at about 70 sites in the US and Europe will be randomized to receive eight infusions of Rituxan (rituximab, Biogen Idec Inc. and R…

Novel Biologic Targets LupusMedPage TodayEpratuzumab differs from rituximab in that it depletes only about 30% of B cells, she explained at the annual meeting of the British Society for Rheumatology. This partial depletion causes phosphorylation and in…

Gilead Initiates Phase 3 Clinical Trial Evaluating GS-1101 for the Treatment …SunHerald.comGS-1101 is an investigational, first-in-class specific inhibitor of the phosphoinositide-3 kinase (PI3K) delta isoform and is being evaluated in combination wi…

In Mexico, New Guidelines Are Now in Effect for the Market Authorization of …MarketWatch (press release)For example, Probiomed already sells six non-originator biologics, including Kikuzubam (rituximab), which is Probiomed's version of Roche'…

Gilead Initiates Phase 3 Clinical Trial Evaluating GS-1101 for the Treatment …EON: Enhanced Online News (press release)GS-1101 is an investigational, first-in-class specific inhibitor of the phosphoinositide-3 kinase (PI3K) delta isoform and is being…

Gilead Initiates Phase 3 Clinical Trial Evaluating GS-1101 for the Treatment …MarketWatch (press release)GS-1101 is an investigational, first-in-class specific inhibitor of the phosphoinositide-3 kinase (PI3K) delta isoform and is being evaluated in …